9. Boston Scientific Corporation (NYSE:BSX)
Number of Hedge Fund Holders: 99
Supplied Share-Price Snapshot: $45.56, up 1.92%
Cardiovascular Innovation Faces a Slower Growth Quarter
Boston Scientific Corporation (NYSE: BSX) offers exposure to minimally invasive medicine through devices used in electrophysiology, structural heart procedures, and vascular interventions. Its investment case depends on physicians adopting its technologies and hospitals maintaining procedure volumes. The stock gained 1.83% for November through November 6, 2026, according to the supplied material, although its quarterly financial performance showed why investors still have reasons to scrutinize the recovery.
Third-quarter 2026 net sales reached $5.138 billion, up 1.5% on reported, operational, and organic measures. Cardiovascular revenue increased to $3.406 billion from $3.343 billion a year earlier, while MedSurg sales edged up 0.6% to $1.733 billion. Management projected a fourth-quarter net sales decline of 1% to 3%. Those figures leave the company with a clear task: translating its product portfolio into a stronger and more consistent growth rate.
Clinical developments provide potential support. On November 2, the company reported that its SIMPLAAFY trial met its six-month primary endpoints, supporting the possibility of simpler medication regimens after implantation of the WATCHMAN FLX Pro device. Its proposed acquisition of Penumbra, Inc. (NYSE: PEN), announced at an enterprise value of approximately $14.5 billion, would also broaden its reach in mechanical thrombectomy and neurovascular treatments. However, the pending transaction brings integration and financing considerations, while pricing pressure in China and uneven heart-device demand remain risks to monitor. Among medical device stocks, the company presents a mix of meaningful innovation and near-term execution challenges.
Ranking Rationale
Boston Scientific Corporation (NYSE: BSX) ranks ninth with 99 hedge fund holders. Its cardiovascular portfolio and potential acquisition benefits support the investment case, but modest quarterly growth and a weaker fourth-quarter sales outlook temper the immediate earnings picture.
